1263187-80-9

Upstream product

• 1263188-76-6 tert-butyl({2-[(4-iodophenoxy)methyl]-2-propenyl}oxy)dimethylsilane 
• 1263188-77-7 3-{[tert-butyl(dimethyl)silyl]oxy}-2-[(4-iodophenoxy)methyl]-1-propanol 
• 1263188-78-8 tert-butyl {3-iodo-2-[(4-iodophenoxy)methyl]propoxy}dimethylsilane 
• 1263188-79-9 2-bromo-1-{3-{[tert-butyl(dimethyl)silyl]oxy}-2-[(4-iodophenoxy)methyl]propyl}-4-nitro-1H-imidazole 
• 1263188-80-2 3-(2-bromo-4-nitro-1H-imidazol-1-yl)-2-[(4-iodophenoxy)methyl]-1-propanol 
• 1263188-81-3 6-[(4-iodophenoxy)methyl]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 128796-39-4 4-trifluoromethylphenylboronic acid 

Relevant academic research and scientific papers

Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy

Abstract Certain biaryl analogues of antitubercular drug PA-824 displayed enhanced in vivo efficacies yet retained some susceptibility towards oxidative metabolism; therefore, two new strategies were explored to address this. Ortho-substitution of the pro

NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES

The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.